HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral
Crescent Biopharma Announces Trial In Progress Presentation For ASCEND Study Of CR-001, At ASCO 2026 Annual Meeting; Multiple CR-001 Clinical Data Readouts Anticipated Beginning In Q1 2027
Crescent Biopharma to Present at May Investor Conferences
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
Crescent Biopharma Q1 EPS $(0.70) Beats $(0.98) Estimate, Sales $1.039M Beat $357.143K Estimate
Crescent Biopharma Announces Grants of Inducement Awards
Crescent Biopharma Files Prospectus For Resale Of Up To ~19.7M Shares By Selling Securityholders From Private Placement And Warrants
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22
Crescent Biopharma: Q4 Earnings Snapshot
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma Q4 EPS $(4.01) Misses $(2.31) Estimate, Sales $10.844M Beat $4.000M Estimate
Crescent Biopharma to Present at March Investor Conferences
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
Crescent Biopharma Announces First Patient Dosed In ASCEND Global Phase 1/2 Clinical Trial For Tumor Medication
Crescent Biopharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
